91Life

🫀At Heart Rhythm Society 2026, we presented work that goes straight to the core of how electrophysiology decisions are made.

“Limitations of Short-Term Monitoring for Detecting Clinically Relevant PVC Burden”
📄PO-04-162

Leart Ajvazaj with Shpat Dobraj, Dredheza Gashi Baraliu, Hortense Gimonet, Dr. Eleonora Gashi
📍 91Life, New York

This study challenges a long-standing assumption: that short-term monitoring is sufficient to guide clinical action.

Across over 246,522 reports, the signal was clear:
– A 24-hour study detects true burden in only 1 in 5 patients
– Even in higher-risk groups, clinically relevant thresholds are frequently missed
– Actionable burden may appear only once every ~57 days

The implication is direct: what we don’t capture, we don’t treat.

We’re proud to bring this level of evidence to the HRS stage—contributing to a broader shift toward continuous, data-driven decision-making in electrophysiology.

A strong moment for the team, and an important conversation for the field.

Bleron Baraliu 91Life

Happy Thanksgiving from all of us at 91Life.
We’re grateful for the partners, clinicians, innovators, and teams who inspire our mission every day.
Thank you for your trust, collaboration, and commitment to advancing patient care.

Wishing you a meaningful holiday. 🤍